A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration Resistant Metastatic Prostate Cancer (CheckMate 9KD: Checkpoint pathway and NivoluMAb clinical Trial Evaluation 9KD)
Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Sponsor: Bristol-Myers Squibb
Enrolling: Male Patients Only
IRB Number: AAAS0351
U.S. Govt. ID: NCT03338790
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called nivolumab when combined with rucaparib, docetaxel or enzalutamide in participants with late stage prostate cancer that was unable to be surgically removed. These three combinations: nivolumab plus rucaparib, nivolumab plus docetaxel, nivolumab plus enzalutamide; have not previously been tested before.
This study is closed
Mark Stein, MD
Do You Qualify?
Do you have a diagnosis of adenocarinoma of the prostate? Yes No
Do you have metastatic disease? Yes No
Have you had analogue or bilateral orchiectomy (surgical/ medical castration of one or both testicles)? If not,are you willing? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator